|
Malignant Neoplasms
|
0.400 |
CausalMutation
|
group |
CGI |
|
|
|
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We have investigated the PTC/retTPC oncogene, an activated form of ret proto-oncogene with a specific rearrangement, in thyroid malignancies.
|
1620547 |
1992 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MEN2A is one of the first cancer syndromes for which DNA screening permits early detection of members at high risk.
|
1355790 |
1992 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The gene(s) responsible for two additional dominantly inherited disorders involving cancer of the medullary thyroid, MEN 2B (MEN2B), and dominantly inherited MTC without additional clinical features (MTC1), also map to this region.
|
1351867 |
1992 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Recent studies of the proto-oncogene c-ret illuminate the basic developmental signalling pathways mediated by receptor tyrosine kinases, as well as the aberrant signalling processes that can lead to cancer.
|
7922346 |
1994 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Thus, germ-line mutations of the RET gene may contribute either to developmental anomalies in HSCR or to inherited predisposition to cancer in MEN 2A.
|
8114939 |
1994 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations of the RET proto-oncogene are the underlying cause of some cases of Hirschsprung disease (HSCR) and the inherited cancer syndromes multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC).
|
7881414 |
1994 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Inherited cancers associated with the RET proto-oncogene.
|
7919923 |
1994 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Oncogenic conversion of RET in these neoplastic syndromes establishes germline transmission of dominant transforming genes in human cancer.
|
7824936 |
1995 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
RET mutations are associated with the dominantly inherited cancer syndromes multiple endocrine neoplasia (MEN) types 2A and 2B and familial medullary thyroid carcinoma (FMTC).
|
7563185 |
1995 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
It has been shown that distinct germline mutations in the RET proto-oncogene are associated with the dominantly inherited cancer syndromes multiple endocrine neoplasia type 2A and 2B (MEN 2A and MEN 2B) and familial medullary thyroid carcinoma (FMTC) as well as Hirschsprung disease (HSCR), a congenital disorder characterised by absent enteric innervation.
|
8570194 |
1995 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
RET is activated through somatic rearrangements in a number of cases of papillary thyroid carcinoma while germ-line point mutations are associated with three inherited cancer syndromes MEN 2A, MEN 2B and FMTC.
|
7478601 |
1995 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The RET proto-oncogene and cancer.
|
7595167 |
1995 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
RET is a receptor tyrosine kinase gene which is responsible for three different inherited cancer syndromes namely multiple endocrine neoplasia type 2A (MEN 2A), type 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC) as well as for Hirschsprung disease (HSCR), a congenital disorder affecting the intestinal motility.
|
7784092 |
1995 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Germline missense mutations within the coding region of the RET proto-oncogene have recently been described in patients with the dominantly inherited cancer syndromes, multiple endocrine neoplasia type 2a (MEN 2a) and familial medullary thyroid carcinoma (FMTC).
|
8829625 |
1996 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Germline mutations in the RET proto-oncogene are seen in the majority of patients with the dominantly inherited cancer syndromes multiple endocrine neoplasia type 2 (MEN 2).
|
9294615 |
1997 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
RET gene alterations as disease-causative mutations have been demonstrated in five different disease entities: Hirschsprung's disease (HD); papillary thyroid carcinoma; and three types of inherited cancer syndromes: multiple endocrine neoplasia (MEN) 2A, MEN 2B, and familial medullary thyroid carcinoma.
|
9035202 |
1997 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Frequent allelic losses on chromosome 9 are seen in a wide variety of human tumors; moreover, two genes (P16 and PTC) whose mutant alleles confer predispositions to some inherited cancer syndromes have been identified on this chromosome.
|
9818027 |
1998 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Radiation-induced rearrangements of chromosome 10 involving the c-ret proto-oncogene have been implicated in the pathogenesis of these cancers.
|
9848713 |
1998 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Germline mutations of RET gene, encoding a receptor tyrosine kinase, have been associated with the MEN2A and MEN2B inherited cancer syndromes.
|
9620546 |
1998 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Germline mutations in the RET proto-oncogene are responsible for three different dominantly inherited cancer syndromes: multiple endocrine neoplasia type 2A (MEN 2A), type 2B (MEN 2B), and familial medullary thyroid carcinoma (FMTC).MTC can also occur sporadically.
|
9950371 |
1999 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
RET proto-oncogene in the development of human cancer.
|
10458257 |
1999 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MEN2 is a cancer syndrome comprising three related clinical subtypes: (1) MEN type 2A (MEN2A; MIM# 171400) characterized by the association of medullary thyroid carcinoma (MTC), pheochromocytoma (Pheo), and hyperparathyroidism; (2) MEN type 2B (MEN2B; MIM# 162300), which includes MTC, Pheo, mucosal neuromas, ganglioneuromatosis of the digestive tract, and skeletal abnormalities; and (3) familial MTC (FMTC; MIM# 155240), defined by the sole occurrence of MTC.
|
10220148 |
1999 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
An intrathyroidal papillary cancer had an N61 ras mutation and a ret/PTC gene rearrangement.
|
9889797 |
1999 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Finally, point mutations of the RET gene are found in familial endocrine syndromes (FMTC; MEN2A and MEN2B), a common feature of which is the medullary thyroid carcinoma, a malignant tumor derived from parafollicular C-cells.
|
10834397 |
2000 |